ScinoPharm Taiwan Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,163	3,406	3,186	3,264	2,762
Revenue Growth (YoY)	-7.13%	6.91%	-2.39%	18.16%	-10.40%
Cost of Revenue	2,067	2,106	1,970	2,013	1,482
Gross Profit	1,096	1,300	1,216	1,251	1,280
Selling, General & Admin	490.3	518.14	543.83	573.88	685.79
Research & Development	497.28	459.36	357.74	271.26	305.95
Operating Expenses	987.53	979.17	901.5	845.28	991.87
Operating Income	108.91	321.04	314.49	405.5	288.62
Interest Expense	-9.87	-8.08	-9.15	-7.91	-6.55
Interest & Investment Income	53.38	61.52	53.63	22.12	19.38
Currency Exchange Gain (Loss)	-	19.23	-16.98	41.27	-7.91
Other Non Operating Income (Expenses)	-5.04	19.57	7.27	-22.88	7.63
EBT Excluding Unusual Items	147.38	413.27	349.26	438.09	301.17
Gain (Loss) on Sale of Assets	-	-4.64	-0.42	-0.76	-0.27
Asset Writedown	-	-1.12	0	0.63	1.38
Legal Settlements	-	5.5	-	-	-
Pretax Income	147.38	413.02	348.84	437.96	302.29
Income Tax Expense	10.42	73.67	61.78	84.74	58.82
Net Income	136.95	339.35	287.06	353.22	243.47
Net Income to Common	136.95	339.35	287.06	353.22	243.47
Net Income Growth	-59.64%	18.22%	-18.73%	45.07%	-13.68%
Shares Outstanding (Basic)	806	791	791	791	791
Shares Outstanding (Diluted)	806	793	792	793	792
Shares Change (YoY)	1.60%	0.07%	-0.04%	0.05%	0.01%
EPS (Basic)	0.17	0.43	0.36	0.45	0.31
EPS (Diluted)	0.17	0.43	0.36	0.45	0.31
EPS Growth	-60.39%	19.21%	-19.41%	45.07%	-13.68%
Free Cash Flow	304.62	470.74	-37.3	530.51	195.4
Free Cash Flow Per Share	0.38	0.59	-0.05	0.67	0.25
Dividend Per Share	-	0.350	0.300	0.360	0.480
Dividend Growth	-	16.67%	-16.67%	-25.00%	-4.00%
Gross Margin	34.66%	38.17%	38.17%	38.32%	46.36%
Operating Margin	3.44%	9.43%	9.87%	12.42%	10.45%
Profit Margin	4.33%	9.96%	9.01%	10.82%	8.81%
Free Cash Flow Margin	9.63%	13.82%	-1.17%	16.25%	7.07%
EBITDA	625.63	792.08	759.82	829.1	655.41
EBITDA Margin	19.78%	23.25%	23.85%	25.40%	23.73%
D&A For EBITDA	516.73	471.04	445.33	423.61	366.79
EBIT	108.91	321.04	314.49	405.5	288.62
EBIT Margin	3.44%	9.43%	9.87%	12.42%	10.45%
Effective Tax Rate	7.07%	17.84%	17.71%	19.35%	19.46%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.